Recent Updates
Recently added Catalysts

BSA204

Phase 1

Dyslipidemias | Small molecule | Cardiovascular |cbdMD, Inc.|Last Updated: Aug 19, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

BSA204 · 1 trial · 1 indication

Phase 1 1
NCT07551505Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)Dyslipidemias
ACTIVE NOT_RECRUITING40 Analytics
PHASE1ACTIVE NOT_RECRUITING
Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)
Dyslipidemias
NCT0755150540
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
From the time of dosing on Day 1 through Day180

Secondary Endpoints

Percent change from Baseline in serum LDL-C and Lp(a) at Day 180
From the time of dosing on Day 1 through Day 180
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort1EXPERIMENTAL -
Cohort2EXPERIMENTAL -
Cohort3EXPERIMENTAL -
Cohort4EXPERIMENTAL -
Cohort5EXPERIMENTAL -

Interventions

NameTypeDescription
BSA204DRUGBSA204 Injection
PlaceboDRUGPlacebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body mass index (BMI) 18 to 30 kg/m2 * Fasting triglycerides (TG) ≤ 4.5 mmol/L * Borderline elevated fasting lipoprotein(a) \[Lp(a)\] levels as defined in the protocol * Fasting low-density lipoprotein cholesterol (LDL-C) within the range specified for the assigned dose cohort...

Countries:China
Unlock Eligibility Criteria